Bristol-Myers Raised Price 30% to Top Competitor for Hepatitis C Drugmaker

Bristol-Myers Squibb Co. (BMY) increased its bid for Inhibitex Inc. (INHX) and its experimental hepatitis C drug twice in five days, raising its offer 30 percent to top an unnamed competitor, according to a filing.

The courtship of Inhibitex began last October, with New York-based Bristol-Myers seeking to purchase Alpharetta, Georgia-based Inhibitex’s experimental drug for $550 million, according to a filing with the U.S. Securities and Exchange Commission. Four months later, on Jan. 7, it had become a $2.5 billion agreement to buy Inhibitex for $26 a share.

The purchase was the second major acquisition of a company for its hepatitis C assets in the past three months. Drugmakers are seeking to enter a developing $20 billion market for hepatitis C medicines that are easier to use and more effective than existing therapies.

Bristol-Myers Chief Executive Officer Lamberto Andreotti was at the head of the negotiations for Inhibitex, going back and forth with an Inhibitex board member as the price went up, according to yesterday’s regulatory filing.

“We did not have a nuke, and we wanted a nuke,” Andreotti said at the J.P. Morgan Healthcare Conference in San Francisco, three days after the deal was announced.

The Inhibitex experimental drug, INX-189, is a nucleotide polymerase inhibitor, or “nuke,” a pill that stops the hepatitis C virus from replicating. “It is the high unmet medical need in hepatitis C that has made us pursue very seriously the acquisition of Inhibitex,” he said.

Patient Population

As many as 170 million people worldwide carry the virus, a bloodborne disease that can lead to liver cirrhosis and cancer, according to the Centers for Disease Control and Prevention in Atlanta.

Gilead Sciences Inc. purchased Pharmasset, the maker of an experimental hepatitis C drug, for $10.8 billion in a deal announced Nov. 21. The price was 94 percent higher than Pharmasset’s 20-day trading average. The 126 percent premium paid by Bristol-Myers over Inhibitex’s average price in the 20 days before the deal ranks as the second-largest on record for a biotechnology or pharmaceutical company worth more than $500 million, according to data compiled by Bloomberg since 1999.

Idenix Pharmaceuticals Inc. (IDIX) and Achillion Pharmaceuticals Inc. (ACHN) are also testing medicines against the virus. Shares of both companies have risen since the Bristol-Myers deal. Idenix has more than doubled in value, closing yesterday at $14.42. Achillion shares have increased 56 percent during the period to $12.37.

First Meeting

The Bristol-Myers deal was at least four months in the making, according to yesterday’s filing. It started at Inhibitex’s Georgia headquarters, with a two-day meeting between three Bristol-Myers executives and Russell Plumb, Inhibitex’s CEO. Two weeks later, after a phone call on Nov. 3 from Bristol- Myers, Plumb had a $550 million offer for INX-189.

On Nov. 4, though, Inhibitex released data from a study that showed the drug “did well in reducing HCV in patients, and was well tolerated, with no serious side effects.” The study results more than doubled Inhibitex’s shares to $8.54.

Over the next month, what started as a look at INX-189 became a broader examination of all of Inibitex. Bristol-Myers examined the company’s “other pipeline assets, its technology platform, and information regarding its discovery, and research and development capabilities” and was given access to “confidential non-public information related to its business and operations,” according to the regulatory filing.

Competitor Emerges

On Dec. 5, Bristol-Myers Chief Financial Officer Charles Bancroft got a phone call from Credit Suisse Group AG, Inhibitex’s bankers. Bancroft was told Inhibitex had an offer from another company to buy it outright and Bristol-Myers could make an offer, as well. The competitor wasn’t identified in the filing.

Bristol-Myers’s board took only a day to decide that an acquisition of Inhibitex was worth exploring, and four days before Christmas told Plumb they intended to make an offer. It came on Jan. 3, at $20 per share, almost double Inhibitex’s stock price of $10.11 that day.

Less than 24 hours later, Inhibitex’s bankers from Credit Suisse were back in touch, telling Bristol-Myers and their bankers at Citigroup Inc. that the rival also had bid $20. Bristol-Myers was given until 6 p.m. the next day to propose their “best and final” offer.

Raising the Bid

Andreotti decided to increase the offer to $23.50 in cash. He also reached out to Gabriele Cerrone, a board member of Inhibitex, e-mailing and calling him to work out the details.

It wasn’t enough, yet. The other bidder matched Bristol- Myers’s offer, the drugmaker’s lawyers were told.

The Bristol-Myers board met Jan. 6. They voted to raise the bid to $26, and Andreotti called Cerrone to say the offer was the best they would get. Inhibitex was given until 2 p.m. the next day -- a Saturday -- to take the deal. If they didn’t, Bristol-Myers would pull back its offer, and “actively pursue the transaction” at $23.50.

The news of the deal was released in a statement at 9:13 p.m. Jan. 7. “This acquisition represents an important investment in the long-term growth of the company,” Andreotti said in announcing the purchase.

To contact the reporter on this story: Drew Armstrong in Washington at darmstrong17@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.